



Press release, september 13, 2024

French network of cooperative groups in oncology (GCO) at ESMO 2024

The GCO network is a French network of ten cooperative groups conducting clinical and translational research in France and in other countries on solid and liquid tumors (lung, digestive, gynecologic, lymphoma, leukemia, myeloma, head and neck, pediatric and brain cancers...). They are all not-for-profit organizations and have been accredited as “French cooperative intergroup of international dimension in the field of cancer” by the French National Cancer Institute (INCa).

SELECTION OF ABSTRACTS



GYNECOLOGIC CANCERS

ARCAGY - Association de Recherche sur les Cancers dont GYnécologiques
**GINECO - Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens et
du sein Cooperative**
Gynecological Cancer Research Group

Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study.

[Proffered Paper session - Presidential symposium](#)

Domenica Lorusso

A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.

[Proffered paper session](#)

Toon Van Gorp

Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012.

[Proffered paper session](#)

Antonio González-Martín

Final overall survival (OS) from the Phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR).

[Mini oral session](#)

Jean Emmanuel Kurtz

A multicentre, open-label, three-arm randomized Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin and Niraparib.

[Mini oral session](#)

Nicole Concin

Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FR α) expression: Results from the PICCOLO trial

[Mini oral session](#)

Angeles A. Secord

COLORECTAL AND NON-COLORECTAL CANCERS

FFCD

Fédération Francophone de Cancérologie Digestive
Francophone Federation of Digestive Tract Cancerology

Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate:

Preliminary results of FFCD 1703 POCHI trial

[Mini oral session](#)

David Tougeron

[4 posters:](#)

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

David Tougeron

Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34 – FFCD 1402 - ADAGE randomized phase III trial

Thomas Aparicio

PRODIGE 86 (FFCD 2103 - GONO) – FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
Thomas Aparicio

Prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: Results from the French prospective FFCD cohort
Gael Roth

GERCOR

Groupe Coopérateur Multidisciplinaire en Oncologie ***Multidisciplinary Oncology Cooperative Group***

Nivolumab plus ipilimumab in microsatellite instability high (MSI)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final survival analysis and prognostic evaluation of GDF-15 in the phase II GERCOR NIPICOL study.

[Poster](#)

Léonard Depotte

G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study.

[Poster](#)

Jean-Baptiste Bachet

HEAD AND NECK CANCERS

GORTEC (Groupe d'Oncologie Radiothérapie Tête Et Cou) ***Head and Neck Oncology Radiotherapy***

Cost effectiveness of stereotactic ablative radiotherapy (SABR) alone in comparison with systemic treatment and SABR in oligometastatic head and neck cancer in the GORTEC 2014-04 OMET randomized phase II study

[Poster](#)

Juliette Thariat

Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial

[Mini oral session](#)

Yungan Tao

LUNG CANCERS

IFCT : Intergroupe Francophone de Cancérologie Thoracique *French Cooperative Thoracic Intergroup*

CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)

Proffered Paper session

Glenwood Goss

Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)

Mini oral session

David Planchard

Durvalumab in treatment-naïve, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial

Poster

Abstract

Valérie Gounant

All abstracts available here:

<https://www.esmo.org/meeting-calendar/esmo-congress-2024>

More information on the GCO network : www.gco-cancer.org

Email : contact@gco-cancer.org

LES GROUPES COOPÉRATEURS MEMBRES DU RÉSEAU GCO

